Preferential detection of catalytically inactive c-erbB-2 by antibodies to unphosphorylated peptides mimicking receptor tyrosine autophosphorylation sites
- PMID: 7624146
Preferential detection of catalytically inactive c-erbB-2 by antibodies to unphosphorylated peptides mimicking receptor tyrosine autophosphorylation sites
Abstract
The c-erbB-2 tyrosine kinase is often overexpressed in human breast cancer, but correlations of receptor expression with tumour behaviour have proven elusive in patients without metastases at diagnosis. To address the possibility that receptor function may be more informative than expression, we previously developed function-specific c-erbB-2 antibodies using synthetic tyrosine-phosphorylated peptide immunogens (Epstein et al., Proc. Natl. Acad. Sci. USA 1992; 89: 10435-10439). Here the converse approach has been taken to determine the functional status of c-erbB-2 receptors detected by antibodies to dephosphorylated (dep) autophosphorylation sequences. In contrast to antiphosphopeptide (apt) antibodies, dep antibodies to the Tyr1248 autophosphorylation site exhibited preferential, but not exclusive, binding to tyrosine-dephosphorylated c-erbB-2. Consistent with this, catalytically active and inactive receptors could not be clearly distinguished by in vitro autophosphorylation experiments in which c-erbB-2 was immunoprecipitated using a monoclonal Tyr1248 dep antibody. A dep antiserum recognizing autophosphorylation sites N-terminal to Tyr1248 exclusively recognized tyrosine-dephosphorylated c-erbB-2 following antibody preabsorption with homologous phosphopeptides. Although indirect, these data are consistent with a model of sequential c-erbB-2 autophosphorylation in which Tyr1248 is the final residue modified. Moreover, since many studies of c-erbB-2 expression have used antibodies to dephosphorylated autophosphorylation sites, these results caution against automatically equating such receptor immunoreactivity with in vivo function or clinical significance.
Similar articles
-
Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.Cancer Res. 1995 May 1;55(9):1946-55. Cancer Res. 1995. PMID: 7728765
-
Identification of autophosphorylation sites of HER2/neu.Cell Growth Differ. 1990 Jan;1(1):3-7. Cell Growth Differ. 1990. PMID: 1706616
-
The role of autophosphorylation in modulation of erbB-2 transforming function.New Biol. 1990 Feb;2(2):187-95. New Biol. 1990. PMID: 1982072
-
The ErbB/HER receptor protein-tyrosine kinases and cancer.Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11. doi: 10.1016/j.bbrc.2004.04.150. Biochem Biophys Res Commun. 2004. PMID: 15158434 Review.
-
Structure-based approaches to inhibition of erbB receptors with peptide mimetics.Immunol Res. 2003;27(2-3):303-8. doi: 10.1385/IR:27:2-3:303. Immunol Res. 2003. PMID: 12857977 Review.
Cited by
-
Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction.Biochem J. 1998 Apr 1;331 ( Pt 1)(Pt 1):113-9. doi: 10.1042/bj3310113. Biochem J. 1998. PMID: 9512468 Free PMC article.
-
Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.Mol Cell Biochem. 2001 Feb;218(1-2):47-54. doi: 10.1023/a:1007249004222. Mol Cell Biochem. 2001. PMID: 11330837
Publication types
MeSH terms
Substances
LinkOut - more resources
Molecular Biology Databases
Research Materials
Miscellaneous